Diagnosing and Treating Community-Acquired Pneumonia

This chapter explores the diagnostic considerations for mycoplasma and Legionella infections in community-acquired pneumonia, focusing on high-risk patient groups. It discusses initial empiric treatments, the complexity of viral etiologies, and the impacts of the COVID-19 pandemic on antibiotic usage. Additionally, it highlights the role of procalcitonin as a biomarker, the importance of risk stratification in therapeutic decisions, and preventive measures to reduce pneumonia incidence.